Outcomes Measures in Subarachnoid Hemorrhage Research
- PMID: 39073651
- DOI: 10.1007/s12975-024-01284-3
Outcomes Measures in Subarachnoid Hemorrhage Research
Abstract
Despite advancements in acute management, morbidity rates for subarachnoid hemorrhage (SAH) remain high. Therefore, it is imperative to utilize standardized outcome scales in SAH research for evaluating new therapies effectively. This review offers a comprehensive overview of prevalent scales and clinical outcomes used in SAH assessment, accompanied by recommendations for their application and prognostic accuracy. Standardized terminology and diagnostic criteria should be employed when reporting pathophysiological outcomes such as symptomatic vasospasm and delayed cerebral ischemia. Furthermore, integrating clinical severity scales like the World Federation of Neurosurgical Societies scale and modified Fisher score into clinical trials is advised to evaluate their prognostic significance, despite their limited correlation with outcomes. The modified Rankin score is widely used for assessing functional outcomes, while the Glasgow outcome scale-extended version is suitable for broader social and behavioral evaluations. Avoiding score dichotomization is crucial to retain valuable information. Cognitive and behavioral outcomes, though frequently affected in patients with favorable neurological outcomes, are often overlooked during follow-up outpatient visits, despite their significant impact on quality of life. Comprehensive neuropsychological evaluations conducted by trained professionals are recommended for characterizing cognitive function, with the Montreal Cognitive Assessment serving as a viable screening tool. Additionally, integrating psychological inventories like the Beck Depression and Anxiety Inventory, along with quality-of-life scales such as the Stroke-Specific Quality of Life Scale, can effectively assess behavioral and quality of life outcomes in SAH studies.
Keywords: Delayed cerebral ischemia; Hemorrhage; Measures; Outcomes; Subarachnoid; Vasospasm.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of Interest: The authors declare no competing interests.
References
-
- Claassen J, Park S. Spontaneous subarachnoid haemorrhage. Lancet. 2022;400(10355):846–62. https://doi.org/10.1016/s0140-6736(22)00938-2 . - DOI - PubMed - PMC
-
- Shah VA, Gonzalez LF, Suarez JI. Therapies for delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2023;39(1):36–50. https://doi.org/10.1007/s12028-023-01747-9 . - DOI - PubMed
-
- Geraghty JR, Lara-Angulo MN, Spegar M, Reeh J, Testai FD. Severe cognitive impairment in aneurysmal subarachnoid hemorrhage: predictors and relationship to functional outcome. J Stroke Cerebrovasc Dis. 2020;29(9):105027. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105027 . - DOI - PubMed - PMC
-
- Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2010;41(8):e519–36. https://doi.org/10.1161/strokeaha.110.581975 . - DOI - PubMed
-
- Garton ALA, Gupta VP, Sudesh S, Zhou H, Christophe BR, Connolly ES Jr. The intracerebral hemorrhage score: changing perspectives on mortality and disability. World Neurosurg. 2020;135:e573–9. https://doi.org/10.1016/j.wneu.2019.12.074 . - DOI - PubMed